about
Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular PolypillTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialCerebral disease in a nationwide Dutch pseudoxanthoma elasticum cohort with a systematic review of the literature.Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management.Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events ofRelation between brown adipose tissue and measures of obesity and metabolic dysfunction in patients with cardiovascular disease.[Syncope; suspect pulmonary embolism, especially in the elderly].Pharmacogenomic insights into treatment and management of statin-induced myopathy.Pharmacological and non-pharmacological interventions to influence adipose tissue function.Metabolic and additional vascular effects of thiazolidinediones.Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects.Cost-effectiveness of a nurse-led internet-based vascular risk factor management programme: economic evaluation alongside a randomised controlled clinical trial.Reliability and agreement of adipose tissue fat fraction measurements with water-fat MRI in patients with manifest cardiovascular disease.Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy womenThe relationship between walking speed and changes in cardiovascular risk factors during a 12-day walking tour to Santiago de Compostela: a cohort study.Excess early postnatal weight gain leads to increased abdominal fat in young childrenBisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus.Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART studyMaraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot StudyRole of adipose tissue in haemostasis, coagulation and fibrinolysis.Perivascular adipose tissue as a cause of atherosclerosis.Infection-induced inflammatory response of adipocytes in vitro.Azithromycin reduces Chlamydia pneumoniae-induced attenuation of eNOS and cGMP production by endothelial cells.Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention.Azithromycin inhibits interleukin-6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae.Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus.Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?Procoagulant and inflammatory response of virus-infected monocytes.Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A.Mechanisms linking obesity to hypertension.Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions.The role of T cells in the development of cardiovascular disease in HIV-infected patients.Paternal or maternal history of cardiovascular disease and the risk of cardiovascular disease in offspring. A systematic review and meta-analysis.Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-LoHigh-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect.Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.Adipose Tissue Dysfunction: Clinical Relevance and Diagnostic Possibilities.Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.
P50
Q26753102-0F406D00-BA85-4739-AD83-A708373DDD5EQ28236480-953C66B5-26E3-4167-A8FC-75160E2E64A8Q30238746-5AC7EEB2-3AC3-4D3A-8978-DAA6BD460404Q30404697-B5ED9952-9F35-4DD5-AD06-8C64E7986A07Q30987054-3FFC7679-B9A0-4700-A8F5-06D1D82CD981Q31157470-0627EBF7-C2F1-401E-A56C-8961AA84DBC1Q33168608-CE43BF78-676E-4F36-80F2-786835E5DB65Q33600104-66BB72D2-DC62-4CC4-9BC9-7817970AA254Q34576535-50BD859A-8FEC-4CA5-88F6-5219F0E3FD25Q34716953-2B1326F6-B71A-490D-811E-D18586767ACDQ35583564-A4A30EF8-B63D-4699-9D0E-4DCA8D399330Q35640489-F0332009-7D88-4AA7-A8D5-A250E75CD031Q35856219-7E19A1AC-80CB-4758-8731-F995AF85B8B8Q35953560-BD8E68C4-FB75-45CF-B827-D034CA9B77F4Q35963055-5FA8B690-0597-4898-9501-17AAE6C551F5Q35977579-BB91A11A-67FD-4727-9D9C-416C039A258DQ36101170-D5DF9F22-3200-4814-A28E-3BC45D9BAF48Q37076080-BE674489-EE71-4726-8E29-A5E47E381CD0Q37112815-BD526CE8-5AB3-46E0-95D1-7E06E642F7B4Q37250180-59EFF090-177F-4AED-9318-4C81015BAE5DQ37491351-6657FF52-F26B-4BF8-9F3B-78B32DF1796CQ37774439-950103AA-2C84-43BC-828C-F8090032B74DQ37857830-F65757C5-3A9A-4915-9060-5DA7DEB5F7B6Q37864081-5194F82A-318A-4A21-8271-042DF5FAF163Q37866364-38B298A8-478C-4C13-AAFB-635C0E629F48Q37866763-67E1ABF3-F836-48C6-97C8-6E5BC20DA83CQ37869013-2B5FDFFF-D45C-4EFA-8806-DC1F40D6CDDBQ37869786-90C6CA7E-CA00-4A72-A944-A6B74D4F5786Q37870946-94080C0E-E0E8-4BD6-86A2-8532160C71C0Q37872373-E623C255-12B2-4B94-BD23-E5E8E487A13AQ37914949-59A54131-F164-4B7E-9587-682D7C3BD928Q38195478-57DF3A87-03E1-4854-AE57-DE6031ABAE76Q38252616-BEC79167-CD8C-4600-A460-75936B61FA4AQ38281256-7DCC7650-3688-4869-ACB0-12ACCD6850E7Q38380588-7BFAD826-1623-4FD3-8AB8-FFDC0B866156Q38392631-8D0F28CE-F16D-46F1-B9D8-B544684753B4Q38451552-907D21B4-D10D-47C1-B31D-72F3D5DBD800Q38464443-D9C0684C-AB1F-458A-B4A6-53CD07B1FA3EQ38804661-74F1FB01-E20D-4EE2-8281-7D10394FBB75Q38860131-91F36623-1A6B-44E3-AF33-47CFA153529B
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-3951-5223
@en
name
Frank L Visseren
@ast
Frank L Visseren
@en
Frank L Visseren
@es
Frank L Visseren
@nl
type
label
Frank L Visseren
@ast
Frank L Visseren
@en
Frank L Visseren
@es
Frank L Visseren
@nl
altLabel
Frank L J Visseren
@en
Frank Visseren
@en
prefLabel
Frank L Visseren
@ast
Frank L Visseren
@en
Frank L Visseren
@es
Frank L Visseren
@nl
P106
P21
P31
P496
0000-0003-3951-5223